Emergence Therapeutics receives follow on seed round
Düsseldorf, Germany, December 9, 2020 — ARQIS advised Emergence Therapeutics AG, a European life science startup, on its extended follow-on seed financing round. The capital comes from a consortium of leading European investors, consisting of Bpifrance (through its InnoBio 2 Fund), Gründerfonds Ruhr, Heidelberg Pharma Research GmbH, High-Tech Gründerfonds, idinvest Partners, Kurma Partners and NRW.Bank. The follow-on seed round was led by High-Tech Gründerfonds and included support from the first pillar of the German government’s €2 billion package of measures for startups.
Jack Elands, CEO of Emergence Therapeutics, said, “We are grateful for the continued support from our investors at this seed stage. Proceeds from the follow-on seed round will be used to advance our development programs focused on Nectin‑4 as a target protein — an increasingly important and clinically validated therapeutic target across a broad spectrum of cancers. In addition, the funding will enable us to accelerate work on additional programs and expand our ADC toolkit to include additional highly innovative linker payload technologies.”
Emergence Therapeutics is a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. Its lead program uses innovative linker and payload technology to address Nectin‑4, an important and validated target for a broad range of cancers. In addition, the company is actively exploring and developing opportunities to develop additional best- or first-in-class ADCs based on therapeutic need. Emergence is based in Duisburg, Germany, and has a subsidiary in Marseille, France.
The ARQIS team led by partner Dr. Christof Alexander Schneider already started advising Emergence Therapeutics in 2019, when the startup was founded via a collaboration between (inter alia) the University of Marseille and Heidelberg Pharma AG. As a result, the firm organized the preceding financing round.
Advisor Emergence Therapeutics: ARQIS Attorneys at Law
Dr. Christof Alexander Schneider (Lead; Transactions; Düsseldorf), Dr. Mauritz von Einem (Tax Law); Associate: Louisa Theresa Graf (Transactions; both Munich)
Niitväli (Frankfurt): Evelyn Niitväli (Antitrust)
ARQIS Attorneys at Law is an independent business law firm operating in Germany and Japan. The firm was founded in 2006 in Düsseldorf, Munich and Tokyo. Around 55 professionals advise domestic and foreign companies at the highest level on German and Japanese business law. For more information, visit www.arqis.com.